Actionable insights — Friday POW!: AstraZeneca (AZN)

1. Buy a pipeline on its hit rate, not on any one readout

1. Count the late-stage readouts scheduled over the next 12–18 months and the company's recent pivotal record (positives vs total last year).
2. Score each week's news as a tally — wins vs losses — rather than reacting to the headline failure.
3. Check that the failures hit non-core programs: does the miss touch the franchise that carries the revenue and growth?
4. Require breadth across therapy areas so "no single setback blows up the investment case."
5. Buy when a cluster of misses has de-rated the stock while the tally and the core franchise remain intact.

• The tally flipping — two or three further misses, especially inside oncology, and any downward revision of management's long-range revenue ambition (the stated bear trigger).

2. Diagnose the discount: name the setbacks and size them

1. When a quality large-cap is 20%+ off its high, list the specific events that created the discount — don't accept "sentiment."
2. Size each one in revenue (third-party estimate cuts are a usable yardstick) against the company's total base.
3. Set the losses against what the business is still delivering: organic growth, EPS growth, margins, reaffirmed guidance.
4. If the named setbacks are small relative to the base and guidance holds, the discount is a repricing of uncertainty — buyable.

• Guidance being cut or the core-EPS growth rate slipping — that converts a sentiment discount into a fundamental one.

3. Screen for a two-yardstick decade low in a stock that was never cheap

1. Plot 10 years of forward P/E and price-to-sales together (the house's preferred yardstick is P/S — sales are harder to fake).
2. Look for both near their decade lows at the same time, and measure the dip from prior peaks.
3. Confirm the stock historically commanded a premium — a structurally cheap stock at its usual multiple is not a signal.
4. Find the last time both lows coincided and check what followed.
5. Compare the forward multiple with the market's to frame relative cheapness.

• Multiples re-rating back toward the mid-range (P/S ~5×, forward P/E ~18–20×) — the point where the mean-reversion leg of the thesis is spent.

4. Find the late-stage asset the market is not yet paying for

1. Scan the pipeline for a drug with replicated positive Phase 3 data (not a single trial) that has drawn little coverage.
2. Ask whether it expands the treatable population beyond what existing drugs reach — the commercial breakthrough is often who it works in, not how well.
3. Check management's peak-sales number and whether it was raised after the data; note regulatory speed (Priority Review) and the decision date.
4. Tie it back to the long-range target: is this the asset that bridges the gap?

• The Q1 2027 FDA decision and the label breadth (all eosinophil levels vs a restricted population).

5. When the preferred breakout is missing, substitute the stock's correction history — and say so

1. Check the chart against your preferred entry pattern (for Haymaker, a breakout from a tight trading range).
2. If it isn't there, state it plainly rather than bending the chart.
3. Look instead at how prior corrections within the long-term up-trend resolved; if each was a buying opportunity, the current pullback can qualify on the same terms.
4. Let valuation carry the entry case when the technical signal is absent.

• A break below the 52-week low (~$146) would break the correction-within-uptrend pattern; recapturing the moving averages would confirm it.